Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.
1. David Osborn appointed as Chief Innovation Officer at Palvella. 2. Osborne has 25 years of experience in topical therapies. 3. QTORIN™ platform expands with second product candidate announcement anticipated by year-end. 4. Palvella targets rare genetic skin diseases with no FDA-approved therapies. 5. QTORIN™ rapamycin gel is under evaluation in clinical trials.